Expression of cytochrome P450 1A1/2 and 3A4 in liver tissues of hepatocellular carcinoma cases and controls from Taiwan and their relationship to hepatitis B virus and aflatoxin B1- and 4-aminobiphenyl-DNA adducts

Biomarkers

Volumn 5, Issue 4, 2000, Pages 295-306

  Zhang, Yu Jing ^a   Chen, Shuyuan ^a   Tsai, Wei Yann ^b   Ahsan, Habibul ^b   Lunn, Ruth M ^c   Wang, Li Yu ^d   Chen, Chien Jen ^e   Santella, Regina M ^a  

^a Mailman Sch Pub Hlth Columbia U ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d TZU CHI UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Carcinogen DNA adducts; Cigarette smoking; Immunohistochemistry

Indexed keywords

4 BIPHENYLAMINE; AFLATOXIN B1; CARCINOGEN; CYTOCHROME P450; CYTOCHROME P450 3A4; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DNA ADDUCT; FEMALE; GENE ACTIVITY; GENETIC VARIABILITY; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; METABOLIC ACTIVATION; PROTEIN EXPRESSION; TAIWAN;

EID: 0342646928     PISSN: 1354750X     EISSN: None     Source Type: Journal    
DOI: 10.1080/135475000413845     Document Type: Article

References (39)

1. ANDERSON, M. R., FARIN, F. M. and OMIECINSKI, C. J. 1998, Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR. DNA and Cell Biology, 17, 231-238.
2. BARTSCH, H., CAPORASO, N., CODA, M., KADLUBAR, F. F., MALAVEILLE, C., SKIPPER, P., TALASAKA, G., TANNENBAUM, S. R. and VINEIS, P. 1990, Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. Journal of the National Cancer Institute, 82, 1826-1831.
3. BEASLEY, R. P. 1982, Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: epidemiologic considerations. Hepatology, 2(suppl.), 21-26.
4. CHANG, T. K., YU, L., MAUREL, P. and WAXMAN, D. J. 1997, Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Research, 57, 1946-1954.
5. CHEN, C. J., LIANG, K. Y., CHANG, A. S., CHANG, Y. C., LU, S. N., LIAW, Y. F., CHANG, W. Y., SHEEN, M. C. and LIN, T. M. 1991, Effects of hepatitis B virus,alcohol drinking, cigarette smoking, and familial tendency on hepatocellular carcinoma. Hepatology, 13, 398-406.
6. CHEN, C. J., YU, M. W., WANG, C. J., HUANG, H. Y. and LIN, W. C. 1993, Multiple risk factors in hepatocellular carcinoma: a cohort study of 13737 male adults in Taiwan. Journal of Gastroenterology and Hepatology, 8, s83-87.
7. CHOMARAT, P., RICE, J. M., SLAGLE, B. L. and WILD, C. P. 1998, Hepatitis B virus-induced liver injury and altered expression of carcinogen metabolising enzymes: the role of the HBx protein. Toxicology Letters, 102-103, 595-601.
8. CONNEY, A. H. 1986, Induction of microsomal cytochrome P-450 enzymes: the first Bernard B. Brodie lecture at Pennsylvania State University. Life Sciences, 39, 2493-2518.
9. CRESPI, C. L., PENMAN, B. W., STEIMEL, D. T., GELBOIN, H. V. and GONZALEZ, F. J. 1991, The development of a human cell line stably expressing human CYP3A4: role in the metabolic activation of aflatoxin B1 and comparison to CYP1A2 and CYP2A3. Carcinogenesis, 12, 355-359.
10. DRAHUSHUK, A. T., MCGARRIGLE, B. P., LARSEN, K. E., STEGEMAN, J. J. and OLSON, J. R. 1998, Detection of CYP1A1 protein in human liver and induction by TCDD in precision-cut liver slices incubated in dynamic organ culture. Carcinogenesis, 19, 1361-1368.
11. 1 metabolism in human liver. Proceedings of the National Academy of Sciences of the USA, 87, 8306-8310.
12. GEUBEL, A. P., PAUWELS, S., BUCHET, J. P., DUMONT, E. and DIVE, C. 1987, Increased CYT P-450 dependent function in healthy HBsAg carriers. Journal of Pharmacology and Therapeutics, 33, 193-196.
13. GUENGERICH, F. P. and SHIMADA, T. 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391-403.
14. GUENGERICH, F. P., JOHNSON, W. W., SHIMADA, T., UENG, Y. F., YAMAZAKI, H. and LANGOUET, S. 1998, Activation and detoxification of aflatoxin B1. Mutation Research, 402, 121-128.
15. HRRIS, C. C. and SUN, T. 1984, Multifactoral etiology of human liver cancer. Carcinogenesis, 5, 697-701.
16. 14C-caffeine breath test. Pharmcology and Toxicology, 77, 247-249.
17. IARC 1992, IARC Monographs on Evaluation of Carcinogenic Risks to Humans (Lyon: IARC), p. 245.
18. IARC 1994, IARC Monographs on the evaluation of carcinogenic risks to humans. Vol. 59 Hepatitis viruses (Lyon: IARC).
19. KAWAJIRI, K. and FUJII-KURIYAMA, Y. 1991, P450 and human cancer. Japanese Journal of Cancer Research, 82, 1325-1335.
20. KIRBY, G. M., WOLF, C. R., NEAL, G. E., JUDAH, D. J., HENDERSON, C. J., SRIVATANAKUL, P. and WILD, C. P. 1993, In vitro metabolism of aflatoxin B1 by normal and tumorous liver tissue from Thailand. Carcinogenesis, 14, 2613-2620.
21. KIRBY, G. M., CHEMIN, I. MONTESANO, R., CHISARI, F. V., LANG, M. A. and WILD, C. P. 1994, Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Molecular Carcinogenesis, 11, 74-80.
22. LANDI, M. T., SINHA, R., LANG, N. P. and KADLUBAR, F. F. 1999, Human cytochrome P4501A2. In P. Vineis, N. Malats, M. Lang, A. d'Errico, N. Caporaso, J. Cuzick and P. Boffeta (eds), Metabolic Polymorphisms and Susceptibility to Cancer (Lyon: IARC), pp. 173-195.
23. LEWIS, D. F. V. 1996, Cytochromes P450 (Bristol: Taylor & Francis).
24. LUNN, R. M., ZHANG, Y. J., WANG, L. Y, CHEN, C. J., LEE, P. H., LEE, C. S., TSAI, W. Y and SANTELLA, R. M. 1997, p53 Mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Research, 57, 3471-3477.
25. MCKINNON, R. A. and MCMANUS, M. E. 1996, Localization of cytochromes P450 in human tissues: implications for chemical toxicity. Pathology, 28, 148-155.
26. MCKINNON, R. A., HALL, P., QUATTROCHI, L. C, TUKEY, R. H. and MCMANUS, M. E. 1991, Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology, 14, 848-856.
27. MURRAY, G. I., FOSTER, C. O., BARNES, T. S., WEAVER, R. J., SNYDER, C. P., EWEN, W. B., MELVIN, W. T. and BURKE, M. D. 1992, Cytochrome P450IA expression in adult and fetal human liver. Carcinogenesis, 13, 165-169.
28. MURRAY, G. I., PATERSON, P. J., WEAVER, R. J., EWEN, S. W. B., MELVIN, W. T. and BURKE, M. D. 1993, The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma. Cancer, 71, 36-43.
29. POIRIER, M. C., FULLERTON, N. F., SMITH, B. A. and BELAND, F. A. 1995, DNA adduct formation and tumorigenesis in mice during the chronic administration of 4-aminobiphenyl at multiple dose levels. Carcinogenesis, 16, 2917-2921.
30. ROSS, R. K., YUAN, J. M., YU, M. C., WOGAN, G. N., QIAN, G. S., Tu, J. T, GROOPMAN, J. D., GAO, Y. T. and HENDERSON, B.E. 1992, Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339, 943-946.
31. SELL, S., HUNT, J. M., DUNSFORD, H. A. and CHISARI, F. V. 1991, Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Research, 51, 1278-1285.
32. SHIMADA, T. and GUENGERICH, F. P. 1989, Evidence for cytochrome P-450nf, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proceedings of the National Academy of Sciences of the USA, 86, 462-465.
33. WANG, L. Y., CHEN, C. J., ZHANG, Y. J., TSAI, W. Y, LEE, P. H., FEITELSON, M. A., LEE, C. S. and SANTELLA, R. M. 1998, 4-Aminobiphenyl-DNA damage in liver tissue of hepatocellular carcinoma patients and controls. American Journal of Epidemiology, 147, 315-323.
34. WANG, L. Y, HATCH, M., CHEN, C. J., LEVIN, B., YOU, S. L., LU, S. N., WU, M. H., WU, W. P., WANG, L. W., WANG, Q., HUANG, G. T., YANG, P. M., LEE, H. S. and SANTELLA, R. M. 1996, Aflatoxin exposure and the risk of hepatocellular carcinoma in Taiwan. International Journal of Cancer, 67, 620-625.
35. WILD, C. P., JANSEN, L. A. M., COVA, L. and MONTESANO, R. 1993, Molecular dosimetry of aflatoxin exposure: contribution to understanding the rnultifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environmental Health Perspectives, 99, 115-122.
36. YAMAZAKI, H., INOUE, K., TURVY, C. G., GUENGERICH, F. P. and SHIMADA, T. 1997, Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metabolism and Disposition, 25, 168-174.
37. YOKOSE, T., DOY, M., TANIGUCHI, T., SHIMADA, T, KAKIKI, M., HORIE, T., MATSUZAKI, Y. and MUKAI, K. 1999, Immunohistochemical study of cytochrome P450 2C and 3A in human nonneolastic and neoplastic tissues. Virchow Archiva A, 434, 401-411.
38. 1-DNA adducts in woodchuck hepatocytes and rat liver tissues by indirect immunofluorescence analysis. Cancer Research, 51, 1720-1725.
39. 1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and non-tumorous liver tissue. Carcinogenesis, 12, 2247-2252.